Žádné výsledky... Zkuste upravit dotaz a/nebo upravit či vypnout filtry.
Nejvíce citovaný článek - PubMed ID 29042358
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study
Annals of the rheumatic diseases.
2018 Feb ;
77 (2) :
234-240.
[epub] 20171017